Review Article - Archives of Dentistry (2020) Volume 2, Issue 2
The Involvement of 18 kDa Translocator Protein (TSPO) in Cigarette Smoke-related Diseases: A Review
Nidal Zeineh1, Abraham Weizman2,3, Moshe Gavish1*
1The Ruth and Bruce Rappaport Faculty of Medicine, Technion Institute of Technology, Haifa 31096, Israel
2Research Unit at Geha Mental Health Center and Laboratory of Biological Psychiatry at Felsenstein Medical Research Center, Petah Tikva, Israel
3Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- *Corresponding Author:
- Moshe Gavish
Received date: August 31, 2020; Accepted date: September 18, 2020
Citation: Zeineh N, Weizman A, Gavish M. The Involvement of 18 kDa Translocator Protein (TSPO) in Cigarette Smoke-related
Diseases: A Review. Arch Dent. 2020; 2(2):35-43.
Copyright: © 2020 Zeineh N, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The 18 kDa translocator protein (TSPO) is mainly located in the outer mitochondrial membrane, widely spread throughout the body
tissues and is abundant particularly in steroid-synthesizing organs. Cigarette smoke (CS) is considered as a major risk factor for
the development of oral, lung, and cardiovascular diseases, as well as cancers. TSPO protein expression is elevated in cells exposed
to CS, which subsequently results in increased TSPO-related cellular processes. CS-induced overexpression of TSPO may lead to
interference with cellular functioning and eventually to tissue damage, and promotes the development of various pathologies, mainly
oral, lung, and cardiovascular diseases. TSPO is involved in intra-cellular functions such as apoptosis, inflammation, proliferation,
and regulation of mitochondrial membrane potential. Hence, the CS-induced upregulation of the TSPO expression may contribute to
the development of malignant and non-malignant oral, lung and cardiovascular diseases, including tumor growth, progression, and
metastasis. Therefore, TSPO may be a target for novel treatments for various CS-associated pathologies.
Cigarette smoke (CS), Translocator protein (TSPO), Cardiovascular disease (CVD), Cancer
Cigarette smoke (CS) is a main risk factor for the development of various diseases, either via direct exposure of tissues to CS [1-3] or indirect exposure of remote organs to CS extracts (CSE) (Figure 1) [4-6]. The harmful impact is induced by exposure to the toxic CS substances, each cigarette contains approximately 7,000 chemicals. Out of these chemicals, 250 compounds are considered harmful to tissues, and 69 of them can be involved in the emergence of cancer .
The 18 kDa translocator protein (TSPO) was previously named as the peripheral benzodiazepine receptor (PBR), as it was first localized in rat kidneys , and can be found in prokaryotes and eukaryotes [9,10]. To be distinguished from the central benzodiazepine receptors (CBR), it was referred as the PBR due its distribution in peripheral tissues outside the central nervous system (CNS), and its affinity to specific benzodiazepines (e.g. Ro5-4864). TSPO is expressed in various tissues across the body, with the highest expression in steroid- synthesizing endocrine organs [11,12], moderate expression in the kidneys and
lungs [13-15], and with relatively low expression in the
brain [16,17]. The TSPO name was attributed to this
mitochondrial protein due to its ability to transport
cholesterol across the outer mitochondrial membrane .
Inside the cell, TSPO is composed of five transmembrane
helices across the outer mitochondrial membrane, which
form a hydrophobic pocket that binds ligands at the
cytosolic side of the mitochondria . In the mitochondrial
membrane, TSPO is found in association with the 32
kDa voltage-dependent anion channel (VDAC), and the
30-kDa adenine nucleotide translocator (ANT) [10,19].
TSPO plays an essential role in various intracellular
functions including: apoptosis [10,20], cell proliferation
[21-23], oxidative stress [24-26], and regulation of the
mitochondrial membrane potential [26,27]. TSPO was found to be involved in the pathophysiology of traumatic
brain injury [28,29], cancer [17,30,31], as well as in
neuroinflammation and neurodegenerative diseases
An interaction was found between CS and TSPO, showing an increase in TSPO protein expression levels starting after 60 mins of exposure of H1299 pulmonary epithelial cells to CS, but not after 30 mins . It is likely that the main mechanism via which CS interferes with the physiological functioning is via induction of hypoxic conditions. In the lungs, the damage associated with CS is related primarily to inflammatory response, oxidative stress and proteolysis in the pulmonary epithelial lining, eventually leading to chronic obstructive pulmonary disease [34-36]. Another study demonstrated that CS-induced damage is related to elevation in the expression of the stress response protein regulated in development and DNA damage response-1 (REDD1). Such CS-induced upregulation of REDD1 expression is a result of the CS-related hypoxia . Another main target for the devastating influence of CS is the cardiovascular system. The high content of free radicals and non-radical oxidants, such as superoxide generation may lead to lipid peroxidation and eventually to oxidative damage. This pathological impact of CS is linked with 3-fold higher risk of atherosclerotic damage to the cardiovascular system. This occurs mainly due to imbalance between the significantly increased oxidant levels and the downregulated protective antioxidants [36,38]. CS
plays an essential role in the development of pulmonary
diseases including chronic obstructive pulmonary disease
(COPD) and cancer . It was shown that a correlation
exists between TSPO expression levels and the cancer
aggressiveness, as upregulation of TSPO expression in
cancer may modulate the activity of various cancer-related
processes, such as cellular proliferation rate, angiogenesis,
tumor cell migratory capability and adhesion . This
role of TSPO in cancer was demonstrated in different
cancer types such as colorectal , breast , prostatic
, ovarian  and colon [43,44] cancers.
The mechanism behind the damage caused by CS remains unclear and poorly understood [45,46]. It is possible that various mechanisms are involved in CS-related oral, pulmonary, and cardiovascular diseases [47-51]. Thus, the elucidation of the cellular and molecular mechanisms behind the occurrence of CS-related diseases is of great importance for the understanding of the pathophysiology of these diseases and the development of novel therapeutic agents.
Relevance of TSPO to Cancer
Alterations in TSPO binding and its expression levels are involved in the development of different pathological conditions. Currently, cancers are of major concern and TSPO expression was previously demonstrated to correlate with cancer aggressiveness .
One of the main cellular roles of TSPO is its antiapoptotic effect , which grants TSPO a protective role against cellular proliferation. Therefore, it seems that increased expression levels of TSPO aims to oppose the cancer’s excessive proliferation rate, growth, and spread of metastasis .
An interaction between CS, TSPO expression, and oral and lung cancers was demonstrated previously [3,52-56]. This interaction is reflected by the increased expression of TSPO in CS-induced oral and lung cancer models [3,53,55]. This interaction may indicate a possible role of
TSPO as a novel target for the treatment of cancer [42-44,57], including oral and lung cancers.
Tumor aggressiveness is correlated with TSPO levels, and the cellular proliferation and survival rates of animals carrying cancerous cells can be attenuated by TSPO ligands [40,58-62]. Hardwick et al. investigated the involvement of over-expression of TSPO in cancerous tissues using southern blot and in situ fluorescence hybridization analysis. They reported elevated expression of the TSPO gene in aggressive metastatic tumor cells . Thus, it seems that elevated TSPO gene expression in aggressive cancers may serve as an indicator of cancer progression. In addition, a positive correlation between TSPO expression and the metastatic potential of tumors was also demonstrated in human brain gliomas and astrocytomas [22,57], as well as in colorectal cancer .
Based on the accumulated data on the interaction between TSPO and cancer, Veenman et al. suggested that TSPO plays a role in cell proliferation and apoptosis, since TSPO ligands inhibit cell proliferation and increased survival rate in animal models of cancer .
CS, TSPO and CS-related Diseases
CS impact on [3H]PK11195 binding to TSPO
Our group assessed the impact of CS on the characteristics of [3H]PK11195 binding to TSPO in various tissues and cell lines. Some studies have shown that exposure to CS is associated with decreases in TSPO binding [6,53,56,64]. It appears that exposure to CS results in a decrease in TSPO binding. As described in Table 1. Exposure of lung cancer cells (H1299 cell line) is associated with a 2-fold decrease in the [3H]PK11195 binding following 60 mins of CS exposure . Another study performed on saliva samples demonstrated a 30% decrease in [3H]PK11195 binding as compared to saliva not exposed to CS . In addition, shorter exposure times to CS was shown to decrease the binding by 75% in cardiomyocytes exposed for 30 mins to CS . Similar effects of CS on TSPO binding were also detected following longer CS exposure time (90 mins). In SCC-15 tongue cancer cells, a decrease in binding levels by 72% was detected at a concentration of 3 nM of [3H]PK11195, and by 56% at a concentration of 6 nM. In the case of SCC-25 tongue cancer cell line, a decrease in binding levels by 64% was seen at a concentration of 3 nM of [3H]
PK11195  (Table 1).
|Cell type||CS exposure|
|Decrease in [3H]PK11195 binding||Reference|
|90||3||64%||Nagler et al. |
|90||3||72%||Nagler et al. |
|Lung epithelium||60||6||2-fold||Nagler et al. |
|Saliva||60||6||30%||Nagler et al. |
|Cardiomyocytes||30||6||75%||Nagler et al. |
Table 1: Decreases in [3H]PK 11195 binding to TSPO following exposure of different cell types to cigarette smoke for different durations.
It is possible that the deficient binding capacity of TSPO is involved in the development of CS-related diseases characterized by uncontrolled proliferation and growth of tissue leading to oral or lung cancer as well as to cardiovascular diseases. TSPO plays a role in cell death and apoptosis [10,65], thus, the CS-associated reduction
in [3H]PK11195 binding to TSPO may lead to uncontrolled cell proliferation.
Cigarette smoke impact on TSPO protein
It was shown that exposure of cells to CS for prolonged time (30, 60, and 120 mins) resulted in increases in TSPO expression levels . As mentioned before, in contrast to this finding, Nagler et al., reported a decrease in binding levels of the TSPO ligand [3H]PK11195 after 30 minutes of exposure of cardiomyocytes  as well as in saliva samples exposed for 60 minutes to CS . It is possible that the upregulation of TSPO protein expression is a consequence of its decreased binding capability. In this manner, via the elevated TSPO protein expression, the cells attempt to provide a protective response to avoid cytotoxic damage. In contrast to the finding of elevated TSPO protein expression subsequent to CS exposure, Gavish et al. demonstrated a decrease in the expression of the tetrameric 72 kDa form of TSPO following 60 mins of CS exposure of H1299 lung cancer cells . Thus, it appears that there is a complex relationship between CS, TSPO binding, and TSPO protein expression.
Cigarette Smoke, TSPO, Oral and Lung
CS is considered as a major risk factor for the development of oral cancer, along with other risk factors such as alcohol consumption, viral infections (mainly HPV-16 and 18), UV light and radiation [67,68]. CS is responsible for most oral cancer cases, and notably 75% of patients with oral cancer are smokers . Tobacco expresses a type of synergism with alcohol, increasing further the risk for oral cancer development in alcohol users. Most oral cancers belong to the squamous cell carcinoma (SCC) family [69,70]. CS is involved also in the development of lung cancer due to the inhaled carcinogens into the alveolar spaces and the direct impact of these carcinogens on lung tissue . Chronic smoking causes accumulating damages and alterations in the pulmonary tissue, and some of these damages are irreversible. The continuous irritation of the pulmonary epithelial lining might result in the appearance of pulmonary diseases such as COPD and other inflammation-related diseases, and eventually may also end in the development of lung cancer that is usually associated with high mortality rates [71,72].
The cancer-related increase in TSPO protein expression in lung cancer cell line (H1299) seems to be upregulated further following CS exposure . This triad interaction (CS, TSPO, and cancer) in both the oral cavity and lung indicates the role of TSPO in CS-induced cancer in these tissues. Usually, oral and lung cancers are present in a more aggressive form in smokers, as compared to nonsmokers [69,73].
This complex association may indicate that TSPO-related pathways play a role in the development and progression of oral and lung cancer induced by CS.
Cigarette Smoke, TSPO, and Cardiovascular
The CS associated with exposure to various oxidizing agents from the combusted cigarettes, resulting in oxidation of various molecules in various tissues throughout the body [74,75].
In the cardiac tissue, the antioxidant system prevents oxidative damage to the myocardium by opposing the production of reactive oxygen species (ROS) . Several studies reported on the impact of CS on TSPO and the TSPO-related mitochondrial processes, which eventually induce oxidative stress, and may cause cell death [3,6]. This association between CS exposure and the degree of the cellular damage was shown to correlate with increased ROS production, oxidative stress, and cell death in parallel to the CS exposure time. This interaction may be involved in the increased risk of CVD, cancers, and inflammatory diseases in chronic smokers [48,76-80].
The incidence of death in myocardial infarction (MI) patients mostly occurs due to coronary heart disease (CHD), with MI proposing a risk factor for heart failure and cardiac arrhythmias [78,79]. A linear correlation described by Whincup and colleagues, demonstrated the increased risk of CHD incidence in relation to increased amount of CS exposure (number of cigarettes smoked daily) . Similarly, another study showed increased relative risk of CHD incidence in association with increased duration of CS exposure in patients under 70 years of age . In contrast to these linear correlations, Law and Wald described a non-linear correlation between the risk for CHD incidence and the increased amount of CS exposure. The authors suggested that the absence of the linear correlation is due to the low threshold of the effect of smoking on the risk to develop a CHD, thus display a more steady incremental fashion 
Penna et al. suggested that the mitochondrial permeability transition pore opening may be altered by the ischemiareperfusion injury to cardiomyocytes, which leads to apoptosis and necrosis to commence and eventually results in MI . Sensitivity to ischemia was shown to be modulated by TSPO ligands, acting as attenuators of ROS generation, which can be further modulated by activation or blockade of the inner membrane anion channel (IMAC) in the mitochondria. Such alterations attenuate the mitochondrial depolarization levels and the duration of the action potential, imposing an antiarrhythmic impact. In this respect, several studies suggested that activation of IMAC resulted in increased sensitivity to ischemia of cardiomyocytes [76,83]. Briefly, the application of TSPO
ligands was shown to possess a cardioprotective effect, via
reducing ROS generation and thus decreasing the risk for
arrhythmia and MI [84,85].
Various studies described the putative role of TSPO and the downstream TSPO-related processes in CS-induced cytotoxic damages in association to disease development. Further comprehensive studies are warranted to clarify the underlying mechanisms in the involvement of TSPO in disease and cancer development. In addition, thorough in vivo investigation of the efficacy of TSPO ligands to prevent or attenuate CS-induced cytotoxicity is needed in appropriate animal models. The accumulated data may promote the development of innovative treatments of CSinduced diseases using TSPO ligands in TSPO-intact and in TSPO-knockdown cells, tissues, and transgenic mice, as well as in human clinical trials.
- Nagler R, Weizman A, Gavish A. Cigarette smoke,
saliva, the translocator protein 18 kDa (TSPO), and oral
cancer. Oral Diseases. 2019 Nov;25(8):1843-9.
- Vainio H, Wilbourn JD, Sasco AJ, Partensky C,
Gaudin N, Heseltine E, et al. Identification of human
carcinogenic risks in IARC monographs. Bulletin du
- Zeineh N, Nagler R, Gabay M, Weizman A, Gavish M.
Effects of cigarette smoke on tspo-related mitochondrial
processes. Cells. 2019 Jul;8(7):694.
- Fricker M, Goggins BJ, Mateer S, Jones B, Kim RY,
Gellatly SL, et al. Chronic cigarette smoke exposure induces
systemic hypoxia that drives intestinal dysfunction. JCI
Insight. 2018 Feb 8;3(3).
- Kamceva G, Arsova-Sarafinovska Z, Ruskovska T,
Zdravkovska M, Kamceva-Panova L, Stikova E. Cigarette
smoking and oxidative stress in patients with coronary
artery disease. Open access Macedonian Journal of
Medical Sciences. 2016 Dec 15;4(4):636-40.
- Nagler R, Zeineh N, Azrad M, Yassin N, Weizman A,
Gavish M. 18-kDa Translocator Protein Ligands Protect
H9C2 Cardiomyocytes from Cigarette Smoke-induced Cell
Death: In Vitro Study. In Vivo. 2020 Mar 1;34(2):549-56.
- Berridge MS, Apana SM, Nagano KK, Berridge
CE, Leisure GP, Boswell MV. Smoking produces rapid rise of [11 C] nicotine in human brain. Psychopharmacology.
2010 May 1;209(4):383-94.
- Braestrup C, Squires RF. Specific benzodiazepine
receptors in rat brain characterized by high-affinity (3H)
diazepam binding. Proceedings of the National Academy
of Sciences. 1977 Sep 1;74(9):3805-9.
- Bonsack F, Sukumari-Ramesh S. TSPO: an
evolutionarily conserved protein with elusive functions.
International journal of molecular sciences. 2018
- Veenman L, Papadopoulos V, Gavish M. Channellike
functions of the 18-kDa translocator protein (TSPO):
regulation of apoptosis and steroidogenesis as part of the
host-defense response. Current Pharmaceutical Design.
2007 Aug 1;13(23):2385-405.
- Souza EB, Anholt RR, Murphy KM, Snyder SH,
Kuhar MJ. Peripheral-type benzodiazepine receptors in
endocrine organs: autoradiographic localization in rat
pituitary, adrenal, and testis. Endocrinology. 1985 Feb
- Papadopoulos V, Baraldi M, Guilarte TR, Knudsen
TB, Lacapère JJ, Lindemann P, et al. Translocator
protein (18 kDa): new nomenclature for the peripheraltype
benzodiazepine receptor based on its structure and
molecular function. Trends in Pharmacological Sciences.
2006 Aug 1;27(8):402-9.
- Anholt RR, De Souza EB, Oster-Granite ML,
Snyder SH. Peripheral-type benzodiazepine receptors:
autoradiographic localization in whole-body sections of
neonatal rats. Journal of Pharmacology and Experimental
Therapeutics. 1985 May 1;233(2):517-26.
- Morohaku K, Phuong NS, Selvaraj V. Developmental
expression of translocator protein/peripheral
benzodiazepine receptor in reproductive tissues. PloS
One. 2013 Sep 5;8(9):e74509.
- Wang HJ, Fan J, Papadopoulos V. Translocator
protein (Tspo) gene promoter-driven green fluorescent
protein synthesis in transgenic mice: an in vivo model to
study Tspo transcription. Cell and Tissue Research. 2012
- Chen MK, Guilarte TR. Translocator protein 18 kDa
(TSPO): molecular sensor of brain injury and repair.
Pharmacology & therapeutics. 2008 Apr 1;118(1):1-7.
- Rupprecht R, Papadopoulos V, Rammes G, Baghai
TC, Fan J, Akula N, et al. Translocator protein (18 kDa)
(TSPO) as a therapeutic target for neurological and
psychiatric disorders. Nature Reviews Drug discovery.
- Jaremko ?, Jaremko M, Giller K, Becker S, Zweckstetter
M. Structure of the mitochondrial translocator protein
in complex with a diagnostic ligand. Science. 2014 Mar
- McEnery MW, Snowman AM, Trifiletti RR, Snyder SH.
Isolation of the mitochondrial benzodiazepine receptor:
association with the voltage-dependent anion channel and
the adenine nucleotide carrier. Proceedings of the National
Academy of Sciences. 1992 Apr 15;89(8):3170-4.
- Veenman L, Gavish M. The role of 18 kDa mitochondrial
translocator protein (TSPO) in programmed cell death, and
effects of steroids on TSPO expression. Current Molecular
Medicine. 2012 May 1;12(4):398-412.
- Beinlich A, Strohmeier R, Kaufmann M, Kuhl H.
Relation of cell proliferation to expression of peripheral
benzodiazepine receptors in human breast cancer cell
lines. Biochemical Pharmacology. 2000 Aug 1;60(3):397-
- Miettinen H, Kononen J, Haapasalo H, Helén P,
Sallinen P, Harjuntausta T, et al. Expression of peripheraltype
benzodiazepine receptor and diazepam binding
inhibitor in human astrocytomas: relationship to cell
proliferation. Cancer Research. 1995 Jun 15;55(12):2691-
- Papadopoulos V. In search of the function of the
peripheral-type benzodiazepine receptor. Endocrine
Research. 2004 Jan 1;30(4):677-84.
- Veenman L, Shandalov Y, Gavish M. VDAC activation
by the 18 kDa translocator protein (TSPO), implications for
apoptosis. Journal of Bioenergetics and Biomembranes.
2008 Jun 1;40(3):199-205.
- Shoukrun R, Veenman L, Shandalov Y, Leschiner S,
Spanier I, Karry R, et al. The 18-kDa translocator protein,
formerly known as the peripheral-type benzodiazepine
receptor, confers proapoptotic and antineoplastic effects
in a human colorectal cancer cell line. Pharmacogenetics
and Genomics. 2008 Nov 1;18(11):977-88.
- Kugler W, Veenman L, Shandalov Y, Leschiner S,
Spanier I, Lakomek M, et al. Ligands of the mitochondrial
18 kDa translocator protein attenuate apoptosis of human
glioblastoma cells exposed to erucylphosphohomocholine.
Analytical Cellular Pathology. 2008 Jan 1;30(5):435-50.
- Veenman L, Alten J, Linnemannstöns K, Shandalov
Y, Zeno S, Lakomek M, et al. Potential involvement of
F 0 F 1-ATP (synth) ase and reactive oxygen species
in apoptosis induction by the antineoplastic agent
erucylphosphohomocholine in glioblastoma cell lines.
Apoptosis. 2010 Jul 1;15(7):753-68.
- Gavish M, Bachman I, Shoukrun R, Katz Y,
Veenman L, Weisinger G, et al. Enigma of the peripheral
benzodiazepine receptor. Pharmacological Reviews. 1999
- Toulmond S, Duval D, Serrano A, Scatton B, Benavides
J. Biochemical and histological alterations induced by
fluid percussion brain injury in the rat. Brain Research.
1993 Aug 20;620(1):24-31.
- Bai M, Rone MB, Papadopoulos V, Bornhop DJ. A novel
functional translocator protein ligand for cancer imaging.
Bioconjugate Chemistry. 2007 Nov 21;18(6):2018-23.
- Vlodavsky E, Soustiel JF. Immunohistochemical
expression of peripheral benzodiazepine receptors in
human astrocytomas and its correlation with grade of
malignancy, proliferation, apoptosis and survival. Journal
of Neuro-oncology. 2007 Jan 1;81(1):1-7.
- Chauveau F, Boutin H, Van Camp N, Dollé F,
Tavitian B. Nuclear imaging of neuroinflammation: a
comprehensive review of [11 C] PK11195 challengers.
European Journal of Nuclear Medicine and Molecular
Imaging. 2008 Dec 1;35(12):2304-19.
- Liu GJ, Middleton RJ, Hatty CR, Kam WW, Chan
R, Pham T, et al. The 18 kDa translocator protein,
microglia and neuroinflammation. Brain Pathology. 2014
- Daijo H, Hoshino Y, Kai S, Suzuki K, Nishi K, Matsuo
Y, et al. Cigarette smoke reversibly activates hypoxiainducible
factor 1 in a reactive oxygen species-dependent
manner. Scientific Reports. 2016 Sep 29;6:34424.
- Demedts IK, Demoor T, Bracke KR, Joos GF, Brusselle
GG. Role of apoptosis in the pathogenesis of COPD and
pulmonary emphysema. Respiratory Research. 2006
- Tagawa Y, Hiramatsu N, Kasai A, Hayakawa K,
Okamura M, Yao J, et al. Induction of apoptosis by cigarette
smoke via ROS-dependent endoplasmic reticulum stress
and CCAAT/enhancer-binding protein-homologous
protein (CHOP). Free Radical Biology and Medicine. 2008
- Yoshida T, Mett I, Bhunia AK, Bowman J, Perez M,
Zhang L, et al. Rtp801, a suppressor of mTOR signaling,
is an essential mediator of cigarette smoke–induced
pulmonary injury and emphysema. Nature Medicine.
- Marangon K, Herbeth B, Lecomte E, Paul-Dauphin
A, Grolier P, Chancerelle Y, et al. Diet, antioxidant status,
and smoking habits in French men. The American Journal
of Clinical Nutrition. 1998 Feb 1;67(2):231-9.
- Bode J, Veenman L, Caballero B, Lakomek M, Kugler
W, Gavish M. The 18 kDa translocator protein influences
angiogenesis, as well as aggressiveness, adhesion,
migration, and proliferation of glioblastoma cells.
Pharmacogenetics and Genomics. 2012 Jul 1;22(7):538-
- Papadopoulos V, Kapsis A, Li H, Amri H, Hardwick
M, Culty M, et al. Drug-induced inhibition of the
peripheral-type benzodiazepine receptor expression and
cell proliferation in human breast cancer cells. Anticancer
- Fafalios A, Akhavan A, Parwani AV, Bies RR, McHugh
KJ, Pflug BR. Translocator protein blockade reduces
prostate tumor growth. Clinical Cancer Research. 2009
- Katz Y, Ben-Baruch G, Kloog Y, Menczer J, Gavish M.
Increased density of peripheral benzodiazepine-binding
sites in ovarian carcinomas as compared with benign
ovarian tumours and normal ovaries. Clinical Science.
- Katz Y, Eitan A, Amiri Z, Gavish M. Dramatic increase
in peripheral benzodiazepine binding sites in human
colonic adenocarcinoma as compared to normal colon.
European Journal of Pharmacology. 1988;148(3):483-4.
- Katz Y, Eitan A, Gavish M. Increase in peripheral
benzodiazepine binding sites in colonic adenocarcinoma.
- Jha P, Peto R. Global effects of smoking, of quitting,
and of taxing tobacco. New England Journal of Medicine.
2014 Jan 2;370(1):60-8.
- Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final
data for 2005. National Vital Statistics Reports. 2008 Apr
- Bhalla DK, Hirata F, Rishi AK, Gairola CG. Cigarette
smoke, inflammation, and lung injury: a mechanistic
perspective. Journal of Toxicology and Environmental
Health, Part B. 2009 Jan 8;12(1):45-64.
- Hasnis E, Reznick AZ, Pollack S, Klein Y, Nagler
RM. Synergistic effect of cigarette smoke and saliva on
lymphocytes—the mediatory role of volatile aldehydes and
redox active iron and the possible implications for oral
cancer. The International Journal of Biochemistry & Cell
Biology. 2004 May 1;36(5):826-39.
- Law MR, Wald NJ. Environmental tobacco smoke
and ischemic heart disease. Progress in Cardiovascular
Diseases. 2003 Jul 1;46(1):31-8.
- Penna C, Perrelli MG, Pagliaro P. Mitochondrial pathways, permeability transition pore, and redox signaling in cardioprotection: therapeutic implications. Antioxidants & Redox Signaling. 2013 Feb 10;18(5):556-
- Skillrud DM, Offord KP, Miller RD. Higher risk of
lung cancer in chronic obstructive pulmonary disease: a
prospective, matched, controlled study. Annals of Internal
Medicine. 1986 Oct 1;105(4):503-7.
- Nagler R, Ben-Izhak O, Savulescu D, Krayzler
E, Akrish S, Leschiner S, et al. Oral cancer, cigarette
smoke and mitochondrial 18 kDa translocator protein
(TSPO)—In vitro, in vivo, salivary analysis. Biochimica et
Biophysica Acta (BBA)-Molecular Basis of Disease. 2010
- Nagler R, Cohen S, Gavish M. The effect of cigarette
smoke on the translocator protein (TSPO) in cultured
lung cancer cells. Journal of Cellular Biochemistry. 2015
- Zeno S, Zaaroor M, Leschiner S, Veenman L, Gavish M.
CoCl2 induces apoptosis via the 18 kDa translocator protein
in U118MG human glioblastoma cells. Biochemistry. 2009
- Nagler R, Savulescu D, Krayzler E, Leschiner S,
Veenman L, Gavish M. Cigarette smoke decreases salivary
18 kDa translocator protein binding affinity-in association
with oxidative stress. Current Medicinal Chemistry. 2010
- Nagler R, Savulescu D, Gavish M. Cigarette smokeinduced
reduction in binding of the salivary translocator
protein is not mediated by free radicals. Biochimie. 2016
- Batarseh A, Li J, Papadopoulos V. Protein kinase
Cε regulation of translocator protein (18 kDa) Tspo gene
expression is mediated through a MAPK pathway targeting
STAT3 and c-Jun transcription factors. Biochemistry.
2010 Jun 15;49(23):4766-78.
- Galiègue S, Casellas P, Kramar A, Tinel N, Simony-
Lafontaine J. Immunohistochemical assessment of the
peripheral benzodiazepine receptor in breast cancer and
its relationship with survival. Clinical cancer research.
2004 Mar 15;10(6):2058-64.
- Han Z, Slack RS, Li W, Papadopoulos V. Expression
of peripheral benzodiazepine receptor (PBR) in human
tumors: relationship to breast, colorectal, and prostate
tumor progression. Journal of Receptors and Signal
Transduction. 2003 Jan 1;23(2-3):225-38.
- Hardwick M, Cavalli LR, Barlow KD, Haddad BR,
Papadopoulos V. Peripheral-type benzodiazepine receptor (PBR) gene amplification in MDA-MB-231 aggressive
breast cancer cells. Cancer Genetics and Cytogenetics.
2002 Nov 1;139(1):48-51.
- Hardwick M, Rone J, Han Z, Haddad B, Papadopoulos
V. Peripheral-type benzodiazepine receptor levels correlate
with the ability of human breast cancer MDA-MB-231 cell
line to grow in scid mice. International Journal of Cancer.
2001 Nov 1;94(3):322-7.
- Hardwick M, Fertikh D, Culty M, Li H, Vidic B,
Papadopoulos V. Peripheral-type benzodiazepine receptor
(PBR) in human breast cancer: correlation of breast cancer
cell aggressive phenotype with PBR expression, nuclear
localization, and PBR-mediated cell proliferation and
nuclear transport of cholesterol. Cancer Research. 1999
- Maaser K, Höpfner M, Jansen A, Weisinger G, Gavish
M, Kozikowski AP, et al. Specific ligands of the peripheral
benzodiazepine receptor induce apoptosis and cell cycle
arrest in human colorectal cancer cells. British Journal of
Cancer. 2001 Dec;85(11):1771-80.
- Gavish A, Krayzler E, Nagler R. Two populations
of TSPO binding sites in oral cancer SCC-15 cells.
Experimental Cell Research. 2017 Jan 1;350(1):279-83.
- Levin E, Premkumar A, Veenman L, Kugler W,
Leschiner S, Spanier I, et al. The peripheral-type
benzodiazepine receptor and tumorigenicity: isoquinoline
binding protein (IBP) antisense knockdown in the C6
glioma cell line. Biochemistry. 2005 Jul 26;44(29):9924-
- Gavish M, Cohen S, Nagler R. Cigarette smoke effects
on TSPO and VDAC expression in a cellular lung cancer
model. European Journal of Cancer Prevention. 2016 Sep
- Neville BW. Update on current trends in oral and
maxillofacial pathology. Head and Neck Pathology. 2007
- Graham S, Dayal H, Rohrer T, Swanson M, Sultz H,
Shedd D, et al. Dentition, diet, tobacco, and alcohol in
the epidemiology of oral cancer. Journal of the National
Cancer Institute. 1977 Dec 1;59(6):1611-8.
- Graham S, Dayal H, Rohrer T, Swanson M, Sultz H,
Shedd D, et al. Dentition, diet, tobacco, and alcohol in
the epidemiology of oral cancer. Journal of the National
Cancer Institute. 1977 Dec 1;59(6):1611-8.
- Mello FW, Melo G, Pasetto JJ, Silva CA,
Warnakulasuriya S, Rivero ER. The synergistic effect of
tobacco and alcohol consumption on oral squamous cell
carcinoma: a systematic review and meta-analysis. Clinical Oral Investigations. 2019 Jul 1:1-1.
- Woodard GA, Jones KD, Jablons DM. Lung cancer
staging and prognosis. InLung Cancer 2016 (pp. 47-75).
- Thorley AJ, Tetley TD. Pulmonary epithelium,
cigarette smoke, and chronic obstructive pulmonary
disease. International journal of chronic obstructive
pulmonary disease. 2007 Dec;2(4):409.
- Rivera GA, Wakelee H. Lung Cancer in Never Smokers.
Advances in Experimental Medicine and Biology. 2016
- Burke A, FitzGerald GA. Oxidative stress and smokinginduced
vascular injury. Progress in Cardiovascular
Diseases. 2003 Jul 1;46(1):79-90.
- Nowak JA, Murray JJ, Oates JA, FitzGerald GA.
Biochemical evidence of a chronic abnormality in platelet
and vascular function in healthy individuals who smoke
cigarettes. Circulation. 1987 Jul;76(1):6-14.
- Motloch LJ, Hu J, Akar FG. The mitochondrial
translocator protein and arrhythmogenesis in ischemic
heart disease. Oxidative medicine and cellular longevity.
2015 Mar 30;2015.
- Krayzler E, Nagler RM. Carbonyl levels and survival
rates in oral cancer cells exposed to cigarette smoke.
Anticancer Research. 2015 Apr 1;35(4):1961-5.
- Lerner DJ, Kannel WB. Patterns of coronary heart
disease morbidity and mortality in the sexes: a 26-year
follow-up of the Framingham population. American Heart
Journal. 1986 Feb 1;111(2):383-90.
- Writing Group Members, Lloyd-Jones D, Adams RJ,
Brown TM, Carnethon M, Dai S, et al. Executive summary:
heart disease and stroke statistics—2010 update: a report
from the American Heart Association. Circulation. 2010
- Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial
ROS-induced ROS release: an update and review.
Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2006
- Whincup PH, Gilg JA, Emberson JR, Jarvis MJ,
Feyerabend C, Bryant A, et al. Passive smoking and risk of
coronary heart disease and stroke: prospective study with
cotinine measurement. BMJ. 2004 Jul 22;329(7459):200-
- In How Tobacco Smoke Causes Disease: The Biology
and Behavioral Basis for Smoking-Attributable Disease: A
Report of the Surgeon General. 2010: Atlanta (GA).
- Akar FG, Aon MA, Tomaselli GF, O’Rourke B. The
mitochondrial origin of postischemic arrhythmias. The
Journal of Clinical Investigation. 2005 Dec 1;115(12):3527-
- Obame FN, Zini R, Souktani R, Berdeaux A, Morin D.
Peripheral benzodiazepine receptor-induced myocardial
protection is mediated by inhibition of mitochondrial
membrane permeabilization. Journal of Pharmacology
and Experimental Therapeutics. 2007 Oct 1;323(1):336-
- Xiao J, Liang D, Zhang H, Liu Y, Li F, Chen YH.
4′-Chlorodiazepam, a translocator protein (18 kDa)
antagonist, improves cardiac functional recovery during
postischemia reperfusion in rats. Experimental Biology
and Medicine. 2010 Apr;235(4):478-86.